ISTH Podcasts

ISTH is the leading international professional society on thrombosis and hemostasis. Listen to our podcast for the latest educational resources in our field.

ISTH Podcasts is a science podcast hosted by Unknown Host, with 77 episodes on record and a Required Pod Score of 80.

Unknown Host hosts ISTH Podcasts, a science show with 77 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  ISTH Podcasts

  FF Miniseries Episode 3

  Oct 2, 202614 min

  In episode 3 of this ISTH Pulse Podcast miniseries, experts explore why next-generation mimetic therapies may be needed in hemophilia A and what they could add to an already evolving treatment landscape. The discussion examines how well current prophylactic options control bleeding, where treatment burden and unmet needs remain and whether less-frequent, subcutaneous dosing could support greater treatment convenience, adherence and access. Our experts also considers how factor VIII inhibitor status may influence treatment decisions and which patients could potentially benefit most as new mimetic therapies continue to develop. This episode is supported by an independent medical education grant from Bayer.

  ListenShow Notes
• 

  ISTH Podcasts

  Factor XI/XIa Inhibitor Therapies: Emerging Approaches to SSP Episode 2

  Sep 30, 202611 min

  In the second episode of a special ISTH Pulse Podcast miniseries, experts explore why next-generation factor mimetics are being developed for hemophilia A and what unmet needs they may help address. The discussion examines the effectiveness of current prophylactic options, ongoing treatment burden and the potential role of less frequent, subcutaneous therapies in supporting treatment adherence and access. The episode also considers how factor VIII inhibitor status may influence treatment needs and what emerging factor mimetics could mean for the evolving hemophilia treatment landscape. This episode is supported by an independent medical education grant from Bayer.

  ListenShow Notes
• 

  ISTH Podcasts

  Factor XI/XIa Inhibitor Therapies: Emerging Approaches to SSP Episode 1

  Sep 28, 202610 min

  In this first episode of a special ISTH Pulse Podcast miniseries, the discussion explores why next-generation mimetic therapies may be needed and where current treatment approaches may still leave gaps. The conversation examines whether existing prophylaxis provides adequate bleeding control, how treatment burden and less-frequent subcutaneous dosing may affect adherence and access and how factor VIII inhibitor status can influence treatment decisions. Tune in for a focused look at the evolving therapeutic landscape and the considerations shaping future approaches to hemophilia care. This episode is supported by an independent medical education grant from Bayer.

  ListenShow Notes
• 

  ISTH Podcasts

  Next Gen Factor Mimetics: Why Are They Needed?

  Sep 23, 202632 min

  In this episode of the ISTH Pulse Podcast, host Julia Sandrin Gauer is joined by Dr. Sanjay Ahuja and Dr. Allison Wheeler to discuss the evolving landscape of factor mimetics for hemophilia A. They explore emerging therapies including Mim8, NXT007 and Inno8, the unmet needs that remain despite advances with emicizumab and factor replacement therapy, and what next-generation approaches could mean for the future of hemophilia care. The conversation also covers dosing, efficacy, safety, treatment switching and the patient populations that may benefit most as new therapeutic options continue to emerge. See a full transcript of this episode here: https://cdn.ymaws.com/www.isth.org/resource/resmgr/2026/transcript_for_podcast_1_sep.pdf

  ListenShow Notes
• 

  ISTH Podcasts

  The GLP-1 Question: What About Blood Clots?

  Sep 15, 202634 min

  In this special episode of the ISTH Pulse Podcast, presented in collaboration with the Vasculearn Network, host Julia Sandrin Gauer is joined by Dr. Christian Ruff and Dr. Rushad Patell to discuss GLP-1 receptor agonists and their potential relationship with venous thromboembolism (VTE). The conversation explores what current evidence tells us about GLP-1 therapies and clotting risk, including the possible roles of weight loss, cardiometabolic health and inflammation. Tune in to hear more about the differences across GLP-1 medications, dual GIP/GLP-1 receptor agonists, patient populations that may warrant additional consideration and important gaps in the existing research.

  ListenShow Notes

Recent guests on ISTH Podcasts. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.